Tags : First Biologic

GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval as First

Shots: The US FDA’s approval follows the open-label study evaluating PK/PD and long-term safety of Nucala (40mg, SC) in children with severe eosinophilic asthma aged 6 to 11yrs. The approval is also supported by results of well-controlled studies assessing Nucala in adults and adolescents The 52wks. long term study of Nucala in pediatric patients aged […]Read More